Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Declines By 65.9%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 35,900 shares, a drop of 65.9% from the August 31st total of 105,400 shares. Currently, 2.6% of the shares of the company are short sold. Based on an average daily trading volume, of 1,330,000 shares, the short-interest ratio is presently 0.0 days.

Windtree Therapeutics Stock Performance

Shares of NASDAQ WINT opened at $3.26 on Wednesday. Windtree Therapeutics has a 52 week low of $2.75 and a 52 week high of $27.00. The stock’s fifty day moving average is $6.93 and its 200 day moving average is $5.57.

Windtree Therapeutics (NASDAQ:WINT) last issued its quarterly earnings results on Monday, August 19th. The company reported ($20.91) EPS for the quarter, missing analysts’ consensus estimates of ($8.11) by ($12.80). On average, analysts predict that Windtree Therapeutics will post -2.38 earnings per share for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.